Research Progress on the Lung Microbiota in Patients 
with COVID-19

Manting Yuan; Xiaoxuan Chen; Ruilin Sun*

doi:10.70711/pmr.v2i3.5476

Research Progress on the Lung Microbiota in Patients with COVID-19

Manting Yuan, Xiaoxuan Chen, Ruilin Sun*

Abstract

The COVID-19 pandemic has brought unprecedented economic, social, and public health challenges. Studies have shown that the
lung microbial community changes in COVID-19 patients. The microbiota impacts metabolism, inflammation, and immune response through
various mechanisms, playing a critical regulatory role in the pathophysiological process of the organism. Disruptions in the lungs microbiota
may impact the severity and clinical prognosis of COVID-19 by influencing the immune system. Currently, the specific action mechanism of
the lung microbiota in COVID-19 is unclear, and we lack reliable indicators to predict and evaluate clinical outcomes. This review explores
the research on the lung microbiota in COVID-19 patients, hoping to identify new approaches for clinical diagnosis and treatment.

Keywords

COVID-19; Lung microbiota; Dysbiosis; Immune imbalance; Review

Full Text:

PDF

Included Database

References

[1] Msemburi W, Karlinsky A, Knutson V, et al. The WHO estimates of excess mortality associated with the COVID-19 pandemic[J]. Nature, 2023, 613(7942): 130-137.

[2] Yamamoto S, Saito M, Tamura A, et al. The human microbiome and COVID-19: A systematic review[J]. PLoS One, 2021, 16(6):

e0253293.

[3] Zhu T, Jin J, Chen M, et al. The impact of infection with COVID-19 on the respiratory microbiome: A narrative review[J]. Virulence,

2022, 13(1): 1076-1087.

[4] Imbert S, Revers M, Enaud R, et al. Lower airway microbiota compositions differ between influenza, COVID-19 and bacteria-related

acute respiratory distress syndromes[J]. Crit Care, 2024, 28(1): 133.

[5] Sommariva M, Le Noci V, Bianchi F, et al. The lung microbiota: role in maintaining pulmonary immune homeostasis and its implications in cancer development and therapy[J]. Cell Mol Life Sci, 2020, 77(14): 2739-2749.

[6] Merenstein C, Bushman FD and Collman RG. Alterations in the respiratory tract microbiome in COVID-19: current observations and

potential significance[J]. Microbiome, 2022, 10(1): 165.

[7] Lira-Lucio JA, Falfn-Valencia R, Ramrez-Venegas A, et al. Lung Microbiome Participation in Local Immune Response Regulation in

Respiratory Diseases[J]. Microorganisms, 2020, 8(7):

[8] Dickson RP. Lung microbiota and COVID-19 severity[J]. Nat Microbiol, 2021, 6(10): 1217-1218.

[9] Bustos IG, Wiscovitch-Russo R, Singh H, et al. Major alteration of Lung Microbiome and the Host Reaction in critically ill COVID-19

Patients with high viral load[J]. Res Sq, 2024:

[10] Yagi K, Huffnagle GB, Lukacs NW, et al. The Lung Microbiome during Health and Disease[J]. Int J Mol Sci, 2021, 22(19):

[11] Khatiwada S and Subedi A. Lung microbiome and coronavirus disease 2019 (COVID-19): Possible link and implications[J]. Hum Microb J, 2020, 17: 100073.

[12] Wang J, Li F and Tian Z. Role of microbiota on lung homeostasis and diseases[J]. Sci China Life Sci, 2017, 60(12): 1407-1415.

[13] Whiteside SA, McGinniss JE and Collman RG. The lung microbiome: progress and promise[J]. J Clin Invest, 2021, 131(15):

[14] Khan I, Bai Y, Zha L, et al. Mechanism of the Gut Microbiota Colonization Resistance and Enteric Pathogen Infection[J]. Front Cell Infect Microbiol, 2021, 11: 716299.

[15] Li R, Li J and Zhou X. Lung microbiome: new insights into the pathogenesis of respiratory diseases[J]. Signal Transduct Target Ther,

2024, 9(1): 19.

[16] Xiang L and Meng X. Emerging cellular and molecular interactions between the lung microbiota and lung diseases[J]. Crit Rev Microbiol, 2022, 48(5): 577-610.

[17] Delgado S, Snchez B, Margolles A, et al. Molecules Produced by Probiotics and Intestinal Microorganisms with Immunomodulatory

Activity[J]. Nutrients, 2020, 12(2):

[18] Xiao Y, Zou H, Li J, et al. Impact of quorum sensing signaling molecules in gram-negative bacteria on host cells: current understanding

and future perspectives[J]. Gut Microbes, 2022, 14(1): 2039048.

[19] Bersch KL, DeMeester KE, Zagani R, et al. Bacterial Peptidoglycan Fragments Differentially Regulate Innate Immune Signaling[J].

ACS Cent Sci, 2021, 7(4): 688-696.

[20] Larsen JM, Steen-Jensen DB, Laursen JM, et al. Divergent pro-inflammatory profile of human dendritic cells in response to commensal

and pathogenic bacteria associated with the airway microbiota[J]. PLoS One, 2012, 7(2): e31976.

[21] Goeteyn E, Grassi L, Van den Bossche S, et al. Commensal bacteria of the lung microbiota synergistically inhibit inflammation in a

three-dimensional epithelial cell model[J]. Front Immunol, 2023, 14: 1176044.

[22] Segal LN, Clemente JC, Tsay JC, et al. Enrichment of the lung microbiome with oral taxa is associated with lung inflammation of a

Th17 phenotype[J]. Nat Microbiol, 2016, 1: 16031.

[23] Gollwitzer ES, Saglani S, Trompette A, et al. Lung microbiota promotes tolerance to allergens in neonates via PD-L1[J]. Nat Med, 2014,

20(6): 642-647.

[24] Ramrez-Labrada AG, Isla D, Artal A, et al. The Influence of Lung Microbiota on Lung Carcinogenesis, Immunity, and

Immunotherapy[J]. Trends Cancer, 2020, 6(2): 86-97.

[25] Fan J, Li X, Gao Y, et al. The lung tissue microbiota features of 20 deceased patients with COVID-19[J]. J Infect, 2020, 81(3): e64-e67.

[26] Shen Z, Xiao Y, Kang L, et al. Genomic Diversity of Severe Acute Respiratory Syndrome-Coronavirus 2 in Patients With Coronavirus

Disease 2019[J]. Clin Infect Dis, 2020, 71(15): 713-720.

[27] Merenstein C, Liang G, Whiteside SA, et al. Signatures of COVID-19 Severity and Immune Response in the Respiratory Tract

Microbiome[J]. mBio, 2021, 12(4): e0177721.

[28] Viciani E, Gaibani P, Castagnetti A, et al. Critically ill patients with COVID-19 show lung fungal dysbiosis with reduced microbial diversity in patients colonized with Candida spp[J]. Int J Infect Dis, 2022, 117: 233-240.

[29] Xie L, Chen L, Li X, et al. Analysis of Lung Microbiome in COVID-19 Patients during Time of Hospitalization[J]. Pathogens, 2023,

12(7):

[30] Han Y, Jia Z, Shi J, et al. The active lung microbiota landscape of COVID-19 patients through the metatranscriptome data analysis[J].

Bioimpacts, 2022, 12(2): 139-146.

[31] Gaibani P, Viciani E, Bartoletti M, et al. The lower respiratory tract microbiome of critically ill patients with COVID-19[J]. Sci Rep,

2021, 11(1): 10103.

[32] Radulescu M and Gant V. Gram-negative pulmonary infections - advances in epidemiology and diagnosis[J]. Curr Opin Pulm Med,

2023, 29(3): 168-173.

[33] De Pascale G, Posteraro B, De Maio F, et al. Lung microbiota composition, respiratory mechanics, and outcomes in COVID-19-related

ARDS[J]. Microbiol Spectr, 2024, 12(4): e0357423.

[34] Kullberg RFJ, de Brabander J, Boers LS, et al. Lung Microbiota of Critically Ill Patients with COVID-19 Are Associated with Nonresolving Acute Respiratory Distress Syndrome[J]. Am J Respir Crit Care Med, 2022, 206(7): 846-856.

[35] Wang L, Cao JB, Xia BB, et al. Metatranscriptome of human lung microbial communities in a cohort of mechanically ventilated COVID-19 Omicron patients[J]. Signal Transduct Target Ther, 2023, 8(1): 432.

[36] Zacharias M, Kashofer K, Wurm P, et al. Host and microbiome features of secondary infections in lethal covid-19[J]. iScience, 2022,

25(9): 104926.

[37] Sulaiman I, Chung M, Angel L, et al. Microbial signatures in the lower airways of mechanically ventilated COVID-19 patients associated with poor clinical outcome[J]. Nat Microbiol, 2021, 6(10): 1245-1258.

[38] Nolan TJ, Gadsby NJ, Hellyer TP, et al. Low-pathogenicity Mycoplasma spp. alter human monocyte and macrophage function and are

highly prevalent among patients with ventilator-acquired pneumonia[J]. Thorax, 2016, 71(7): 594-600.

[39] Tangye SG, Palendira U and Edwards ES. Human immunity against EBV-lessons from the clinic[J]. J Exp Med, 2017, 214(2): 269-283.

[40] Espericueta V, Manughian-Peter AO, Bally I, et al. Recombinant C1q variants modulate macrophage responses but do not activate the

classical complement pathway[J]. Mol Immunol, 2020, 117: 65-72.

[41] Hetzel M, Ackermann M and Lachmann N. Beyond Big Eaters: The Versatile Role of Alveolar Macrophages in Health and Disease[J].

Int J Mol Sci, 2021, 22(7):

[42] Bohlson SS, OConner SD, Hulsebus HJ, et al. Complement, c1q, and c1q-related molecules regulate macrophage polarization[J]. Front

Immunol, 2014, 5: 402.

[43] Blackburn SD, Shin H, Haining WN, et al. Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral

infection[J]. Nat Immunol, 2009, 10(1): 29-37.

[44] Wang B, Zhang L, Wang Y, et al. Alterations in microbiota of patients with COVID-19: potential mechanisms and therapeutic

interventions[J]. Signal Transduct Target Ther, 2022, 7(1): 143.

[45] Stavropoulou E, Kantartzi K, Tsigalou C, et al. Unraveling the Interconnection Patterns Across Lung Microbiome, Respiratory Diseases,

and COVID-19[J]. Front Cell Infect Microbiol, 2020, 10: 619075.

[46] Patel S and Wadhwa M. Therapeutic use of specific tumour necrosis factor inhibitors in inflammatory diseases including COVID-19[J].

Biomed Pharmacother, 2021, 140: 111785.

[47] Karki R, Sharma BR, Tuladhar S, et al. Synergism of TNF-? and IFN-? Triggers Inflammatory Cell Death, Tissue Damage, and Mortality in SARS-CoV-2 Infection and Cytokine Shock Syndromes[J]. Cell, 2021, 184(1): 149-168.e117.

[48] Cesta MC, Zippoli M, Marsiglia C, et al. Neutrophil activation and neutrophil extracellular traps (NETs) in COVID-19 ARDS and

immunothrombosis[J]. Eur J Immunol, 2023, 53(1): e2250010.

[49] Li J, Qin Y, Chen Y, et al. Mechanisms of the lipopolysaccharide-induced inflammatory response in alveolar epithelial cell/macrophage

co-culture[J]. Exp Ther Med, 2020, 20(5): 76.

DOI: http://dx.doi.org/10.70711/pmr.v2i3.5476

Refbacks

There are currently no refbacks.